Other substances

Mycophenolic acid

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

3
 Supporting references
0
 Contradictory references
22
 AI-suggested references
0
 Clinical trials

 

Supporting references

Link Tested on Impact factor Notes Publication date
Identification of Candidate COVID-19 Therapeutics using hPSC-derived Lung Organoids
Preprint 		hPSC-derived lung organoids

inhibitor of SARS-CoV-2 entry

 May/05/2020
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
Small molecule 		in silico 42.78 Apr/30/2020
Identification of Drugs Blocking SARS-CoV-2 Infection using Human Pluripotent Stem Cell-derived Colonic Organoids
Preprint 		human pluripotent stem cell-derived colonic organoids May/02/2020

AI-suggested references

Link Publication date
Weak antibody response to three doses of mRNA vaccine in kidney transplant recipients treated with belatacept.
Sep/12/2021
The Potential Use of Cyclosporine Ultrafine Solution Pressurised Metered-Dose Inhaler in the Treatment of COVID-19 Patients.
Nov/24/2021
Immune Responses to SARS-CoV-2 Infection and Vaccination in Dialysis Patients and Kidney Transplant Recipients
Dec/21/2021
State-of-the-art tools to identify druggable protein ligand of SARS-CoV-2
Mar/07/2022
Antibody Response to mRNA Vaccines against SARS-CoV-2 with Chronic Kidney Disease, Hemodialysis, and after Kidney Transplantation
Dec/28/2021
Antiviral activities of mycophenolic acid and IMD-0354 against SARS-CoV-2
Jun/10/2021
Identification of SARS-CoV-2 Inhibitors using Lung and Colonic Organoids
Oct/28/2020
Evaluating the antibody response to SARS-COV-2 vaccination amongst kidney transplant recipients at a single nephrology centre
Mar/10/2022
In silico molecular docking analysis for repurposing therapeutics against multiple proteins from SARS-CoV-2.
Aug/03/2020
High-Throughput Screening of an FDA-Approved Drug Library Identifies Inhibitors against Arenaviruses and SARS-CoV-2
Sep/30/2021
Screening Potential Drugs for COVID-19 Based on Bound Nuclear Norm Regularization
Oct/07/2021
Various interferon (IFN)-inducible transmembrane (IFITM) proteins for COVID-19, is there a role for the combination of mycophenolic acid and interferon?
Aug/14/2020
Identification of broad anti-coronavirus chemical agents for repurposing against SARS-CoV-2 and variants of concern
Jan/15/2022
Screening for natural and derived bio-active compounds in preclinical and clinical studies: One of the frontlines of fighting the coronaviruses pandemic.
Aug/29/2020
Computational Determination of Potential Multiprotein Targeting Natural Compounds for Rational Drug Design Against SARS-COV-2
Jan/28/2021
Humoral Response of Renal Transplant Recipients to the BNT162b2 SARS-CoV-2 mRNA Vaccine Using Both RBD IgG and Neutralizing Antibodies
Jul/27/2021
The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant
Sep/03/2021
BNT162b2 Third Booster Dose Significantly Increases the Humoral Response Assessed by Both RBD IgG and Neutralizing Antibodies in Renal Transplant Recipients
Mar/21/2022
Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study.
May/03/2021
Serological Response to Three, Four and Five Doses of SARS-CoV-2 Vaccine in Kidney Transplant Recipients
Oct/16/2020
In silico molecular docking analysis for repurposing approved antiviral drugs against SARS-CoV-2 main protease.
Jun/03/2021
BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response.
Apr/21/2021
Export (.csv)